KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Short-term Investments: 2009-2024

Historic Short-term Investments for Ionis Pharmaceuticals (IONS) over the last 16 years, with Dec 2024 value amounting to $2.1 billion.

  • Ionis Pharmaceuticals' Short-term Investments fell 11.49% to $1.9 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year decrease of 11.49%. This contributed to the annual value of $2.1 billion for FY2024, which is 6.40% up from last year.
  • As of FY2024, Ionis Pharmaceuticals' Short-term Investments stood at $2.1 billion, which was up 6.40% from $1.9 billion recorded in FY2023.
  • Ionis Pharmaceuticals' 5-year Short-term Investments high stood at $2.1 billion for FY2024, and its period low was $1.2 billion during FY2021.
  • In the last 3 years, Ionis Pharmaceuticals' Short-term Investments had a median value of $1.9 billion in 2023 and averaged $1.9 billion.
  • In the last 5 years, Ionis Pharmaceuticals' Short-term Investments decreased by 17.70% in 2020 and then soared by 37.30% in 2022.
  • Over the past 5 years, Ionis Pharmaceuticals' Short-term Investments (Yearly) stood at $1.5 billion in 2020, then declined by 16.65% to $1.2 billion in 2021, then surged by 37.30% to $1.7 billion in 2022, then grew by 12.95% to $1.9 billion in 2023, then grew by 6.40% to $2.1 billion in 2024.